Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization.

The objective of this study was to optimize and characterize a novel polymeric mixed micelle composed of Pluronic P123 and F127 loaded with paclitaxel (PTX). A Doehlert matrix design was utilized to investigate the effect of four variables, namely P123 mass fraction, amount of water, feeding of PTX and hydration temperature on the responses including drug-loading coefficient (DL %), encapsulation ratio (ER %) and the percentage of PTX precipitated from the drug-loaded mixed micelles after 48 h at 37 (PTX precipitated %) for improvement of drug solubilization efficiency and micelle stability. PTX-loaded P123/F127 mixed micelles were prepared by thin-film hydration method. The optimized formulation showed a particle size of about 25 nm with ER %>90%, and a sustained release behavior compared to Taxol. Micelle formation was confirmed by NMR spectroscopy. The mixed micelles had a low CMC of 0.0059% in water. In addition, micelle stability studies implied that introduction of Pluronic F127 (33 wt%) into P123 micelle system significantly increased the stability of PTX-loaded micelles. More importantly, in vitro cytotoxicity was assessed using human lung adenocarcinoma cell lines SPC-A1 and A-549 and was compared to Taxol and the free drug. The cell viability assay against A-549 cells exhibited the 50% inhibition concentration (IC50) of PTX-loaded P123/F127 mixed micelles (0.1 microg/ml) was much lower than those of Taxol injection (0.4 microg/ml) and the free PTX (1.7 microg/ml). Therefore, PTX-loaded P123/F127 mixed micelles may be considered as an effective anticancer drug delivery system for cancer chemotherapy.

[1]  Soo-Jeong Lim,et al.  Cyclooxygenase-independent down-regulation of multidrug resistance–associated protein-1 expression by celecoxib in human lung cancer cells , 2005, Molecular Cancer Therapeutics.

[2]  Alexander V Kabanov,et al.  Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Xiao-ling Fang,et al.  Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123 , 2006, Acta Pharmacologica Sinica.

[4]  I. Kwon,et al.  Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(ε-caprolactone) copolymer as a carrier for paclitaxel , 2003 .

[5]  Cunxian Song,et al.  PCL/poloxamer 188 blend microsphere for paclitaxel delivery: Influence of poloxamer 188 on morphology and drug release , 2007 .

[6]  K. Sakurai,et al.  Preparation of nanoparticles consisted of poly(L-lactide)-poly(ethylene glycol)-poly(L-lactide) and their evaluation in vitro. , 1999, International journal of pharmaceutics.

[7]  P. Dallas,et al.  Evaluation and simultaneous optimization of some pellets characteristics using a 3(3) factorial design and the desirability function. , 2002, International journal of pharmaceutics.

[8]  Alexander V Kabanov,et al.  Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. , 2002, Critical reviews in therapeutic drug carrier systems.

[9]  Cristina M Quintella,et al.  Doehlert matrix: a chemometric tool for analytical chemistry-review. , 2004, Talanta.

[10]  A. Kabanov,et al.  Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. , 1996, British Journal of Cancer.

[11]  Christine Jérôme,et al.  Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Xiaoling Fang,et al.  Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. , 2007, International journal of pharmaceutics.

[13]  S. Gaisford,et al.  Diode-array UV spectrometric evidence for cooperative interactions in binary mixtures of Pluronics F77, F87, and F127 , 1997 .

[14]  G. Badun,et al.  Interaction of tumor and normal blood cells with ethylene oxide and propylene oxide block copolymers , 1999, FEBS letters.

[15]  John K. Jackson,et al.  Development of amphiphilic diblock copolymers as micellar carriers of taxol , 1996 .

[16]  V. Torchilin,et al.  Structure and design of polymeric surfactant-based drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[17]  H. Ueno,et al.  Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.

[18]  A. Kabanov,et al.  Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. , 1996, Bioconjugate chemistry.

[19]  James B. Mitchell,et al.  The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumor cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[20]  F. Dosio,et al.  Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Xuesi Chen,et al.  A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Yongzhong Wang,et al.  Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles , 2008, Archives of pharmacal research.

[23]  Alexander V Kabanov,et al.  Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. , 2003, Advanced drug delivery reviews.

[24]  Alexander V Kabanov,et al.  Micellar formulations for drug delivery based on mixtures of hydrophobic and hydrophilic Pluronic block copolymers. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[25]  W. Pitt,et al.  Drug delivery in polymeric micelles: from in vitro to in vivo. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Jiangning Chen,et al.  Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)-poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles. , 2003, Biomaterials.

[27]  D. Chiappetta,et al.  Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[28]  T. Baykara,et al.  Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[29]  R. Liggins,et al.  Paclitaxel-loaded poly(L-lactic acid) microspheres 3: blending low and high molecular weight polymers to control morphology and drug release. , 2004, International journal of pharmaceutics.

[30]  Kinam Park,et al.  A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[31]  E. Monti,et al.  Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. , 2002, Toxicology in vitro : an international journal published in association with BIBRA.

[32]  Kinam Park,et al.  Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[33]  T. Okano,et al.  Incorporation of the Anticancer Agent KRN5500 into Polymeric Micelles Diminishes the Pulmonary Toxicity , 2002, Japanese journal of cancer research : Gann.

[34]  Si-Shen Feng,et al.  The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. , 2006, Biomaterials.

[35]  Kinam Park,et al.  Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[36]  J. Cook,et al.  Cremophor EL, solvent for paclitaxel, and toxicity , 1993, The Lancet.

[37]  Chiraphon Chaibundit,et al.  Micellization and gelation of mixed copolymers P123 and F127 in aqueous solution. , 2007, Langmuir : the ACS journal of surfaces and colloids.

[38]  A. Kabanov,et al.  An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[39]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  V. Alakhov,et al.  Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. , 1996, Cancer research.

[41]  T. Tadros,et al.  Physical Conjugation of (Tri-) Block Copolymers to Liposomes toward the Construction of Sterically Stabilized Vesicle Systems , 1999 .

[42]  Alexander V. Kabanov,et al.  Relationship between pluronic block copolymer structure, critical micellization concentration and partitioning coefficients of low molecular mass solutes , 2000 .

[43]  C. van Nostrum,et al.  The effect of core composition in biodegradable oligomeric micelles as taxane formulations. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  A. Kabanov,et al.  Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials , 1999 .

[45]  D. Kerr,et al.  Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer , 2004, British Journal of Cancer.

[46]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[47]  J. Sasaki,et al.  Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells. , 2008, Biochemical pharmacology.

[48]  Dae-Duk Kim,et al.  Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[49]  Kinam Park,et al.  Hydrotropic polymer micelle system for delivery of paclitaxel. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[50]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[51]  Alexander V Kabanov,et al.  Optimal Structure Requirements for Pluronic Block Copolymers in Modifying P-glycoprotein Drug Efflux Transporter Activity in Bovine Brain Microvessel Endothelial Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[52]  Stuart J. Williams,et al.  Diode-array UV spectrometric evidence for a concentration dependent phase transition in dilute aqueous solutions of pluronic F87 (poloxamer 237) , 1995 .

[53]  D. Faulds,et al.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. , 1994, Drugs.

[54]  I. Szleifer,et al.  Spontaneous liposome formation induced by grafted poly(ethylene oxide) layers: theoretical prediction and experimental verification. , 1998, Proceedings of the National Academy of Sciences of the United States of America.